Detection of complete response to imatinib mesylate (Glivec[®]/Gleevec[®]) with 18F-FDG PET/CT for low-grade endometrial stromal sarcoma

Mehmet Emin Kalender · Alper Sevinc ·
Mustafa Yilmaz · Coskun Ozsarac ·
Celalettin Camci

Published online: 20 August 2008
© Springer-Verlag 2008

Erratum to: Cancer Chemother Pharmacol
DOI 10.1007/s00280-008-0786-7

Table 1 was given incorrectly. The correct table is given here.

Table 1 The time schedule of FDG PET/CT scans with maximum SUV and HU of the mass

PET/CT	Time of PET/CT	Maximum SUV	HU
Fig. 1a	After three cycles of chemotherapy	2.7	39
Fig. 1b	After six cycles of chemotherapy	3.1	34
Fig. 1c	After three months of hormonotherapy	4	37
Fig. 1d	Five months after imatinib mesylate	2.3	33

SUV standardized uptake value, *HU* Hounsfield Units

The online version of the original article can be found under doi: [10.1007/s00280-008-0786-7](https://doi.org/10.1007/s00280-008-0786-7).

M. E. Kalender (✉) · A. Sevinc · M. Yilmaz ·
C. Ozsarac · C. Camci
Department of Medical Oncology, Medical Faculty,
Gaziantep University, Gaziantep Oncology Hospital,
27310 Gaziantep, Turkey
e-mail: kalender@gantep.edu.tr